CN107149140A - 一种含灵芝菌丝体的营养健康食品 - Google Patents
一种含灵芝菌丝体的营养健康食品 Download PDFInfo
- Publication number
- CN107149140A CN107149140A CN201710345834.XA CN201710345834A CN107149140A CN 107149140 A CN107149140 A CN 107149140A CN 201710345834 A CN201710345834 A CN 201710345834A CN 107149140 A CN107149140 A CN 107149140A
- Authority
- CN
- China
- Prior art keywords
- parts
- ganoderma lucidum
- lucidum mycelium
- powder
- nutritious
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 77
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 76
- 235000008935 nutritious Nutrition 0.000 title claims abstract description 26
- 235000001497 healthy food Nutrition 0.000 title claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 61
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 241000251468 Actinopterygii Species 0.000 claims abstract description 25
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 25
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 25
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 22
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 22
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract description 20
- 239000000905 isomalt Substances 0.000 claims abstract description 20
- 235000010439 isomalt Nutrition 0.000 claims abstract description 20
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 20
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 12
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 12
- 229940082787 spirulina Drugs 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims description 19
- 241000195493 Cryptophyta Species 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 239000000203 mixture Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 230000000050 nutritive effect Effects 0.000 abstract description 5
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 26
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 12
- 108010073771 Soybean Proteins Proteins 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- -1 coumarin glucoside Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229940001501 fibrinolysin Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种含灵芝菌丝体的营养健康食品,它的原料及重量百分比为:灵芝菌丝粉50~65份,活性地龙蛋白40~65份,大豆肽粉10~25份,海洋鱼低聚肽10~15份,螺旋藻10~15份,大豆磷脂5~10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份;本发明以灵芝菌丝粉、活性地龙蛋白为主要原料成分,同时加入易于人体吸收的动物多肽、植物多肽;使保健功效能够充分发挥。本发明的营养健康食品不仅营养价值高,富含多糖,具有一定的防治疾病的功效。
Description
技术领域
本发明属于食品技术领域,具体是涉及一种灵芝菌丝体食品。
背景技术
灵芝又称林中灵、琼珍(学名:Ganoderma Lucidum Karst)是多孔菌科真菌灵芝的子实体。浙江龙泉、黑龙江、吉林、河北、山东、安徽霍山、江苏、江西、湖南、贵州、福建、广东、广西等省份均有种植。其中浙江龙泉、安徽、山东泰安一带的灵芝种植规模较为集中。
灵芝的生长分为三个阶段:
1、子实体阶段:木本或草本,俗称灵芝全草,多糖含量1%。
2、孢子体阶段:孢子体就是灵芝的种子,是极其细微的传宗接代的胞器,单个的孢子极其细小,只有几微米至十几微米,肉眼无法看清,人们平时所见的是由无数个孢子集中起来的,呈粉末状,俗称灵芝孢子粉。多糖含量3%。
3、菌丝体阶段:孢子萌芽后,产生的黄白色丝状物质叫做菌丝体,这是灵芝生命力最旺盛的阶段,多糖含量15%。
也就是说,灵芝孢子(灵芝种子)萌发形成菌丝。灵芝菌丝不断地分解,吸收养份,在合适的光照,空气,温度等其它条件配合时就形成了灵芝子实体。子实体成熟后弹射孢子粉,也就形成了灵芝的生活史。灵芝子实体所需要的构成物质,有一半以上的营养物质来源于菌丝体中的贮存养份。所以菌丝体的营养含量和灵芝多糖的含量一般上会比灵芝子实体和灵芝孢子粉高出许多倍。
灵芝菌丝体主要含糖类(还原糖和多糖,占15%以上)、氨基酸、多肽、蛋白质、真菌溶菌酶(fungal lysozyme)、甘露醇、海藻糖、麦角甾醇、三萜类、香豆精甙、挥发油和硬脂酸等。灵芝粉末呈浅棕色、棕褐色至紫褐色。菌丝散在或粘结成团,无色或淡棕色,细长,稍弯曲,有分枝,直径2.5~6.5微米。孢子褐色,卵形,顶端平截,外壁无色,内壁有疣状突起,长8~12微米,宽5~8微米。
灵芝药用在我国已有2000多年的历史,被历代医药家视为滋补强壮、扶正固本的神奇珍品。灵芝对神经衰弱、高脂血症、冠心病心绞痛、心律失常、克山病、高原不适症、肝炎、出血热、消化不良、气管炎等各有不同程度的疗效。对如下几方面均有作用:
1、对中枢神经系统。2、具有调节心血管系统的作用。3、具有抗血小板聚集及抗血栓作用。4、对呼吸系统有作用。5、对代谢和内分泌功能的影响:小鼠腹腔注射灵芝多糖BN3C(即D6)能促进血清、肝脏及骨髓的蛋白质与核酸的合成,加速骨髓细胞分裂、增殖,还能增加小鼠肝匀浆细胞P-450的含量,提高肝脏的解毒功能。灵芝浸膏对烫伤动物可增加血浆皮质醇的含量。6、具有保肝作用。7、具有抗氧化、延缓衰老作用。9、抗炎作用。10、抗肿瘤作用。11、免疫调节作用。12、灵芝保护放化疗损伤作用。
虽然灵芝的保健功效作用明显,但目前市场上的灵芝产品种类非常单一,功效上也比较单一,难以增强其功效作用,在一定程度上造成营养浪费。
发明内容
本发明的目的是提供一种含灵芝菌丝体的营养健康食品。本发明以灵芝菌丝粉、活性地龙蛋白为主要原料成分,同时加入易于人体吸收的动物多肽、植物多肽;使保健功效能够充分发挥。本发明的营养健康食品不仅营养价值高,富含多糖,具有一定的防治疾病的功效。
本发明的含灵芝菌丝体的营养健康食品的原料及重量份数为灵芝菌丝体粉50~65份,活性地龙蛋白40~65份,大豆肽粉10~25份,海洋鱼低聚肽10~15份,螺旋藻10~15份,大豆磷脂5~10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份
作为技术方案的优选,本发明的含灵芝菌丝体的营养健康食品的原料及重量份数为:灵芝菌丝体粉55~60份,活性地龙蛋白45~50份,大豆肽粉10~15份,海洋鱼低聚肽5~10份,螺旋藻5~10份,大豆磷脂5~10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份。
作为技术方案的优选,本发明的含灵芝菌丝体的营养健康食品的原料及重量份数为:灵芝菌丝体粉55份,活性地龙蛋白45份,大豆肽粉10份,海洋鱼低聚肽10份,螺旋藻10份,大豆磷脂10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份。在这个配比下,营养价值含量最高,具有明显的抗氧化、延缓衰老、提高免疫力,有效调节血脂、血压的平衡,易于人体吸收,保健功效好。
作为技术方案的优选,本发明中的灵芝菌丝粉和活性地龙蛋白过60~150目筛。
本发明食品的制备方法是:先按配比称取原料,再将其进行充分粉碎混合、搅拌均匀,杀菌消毒,然后用常规方法灌入胶囊做成胶囊剂,采用常规方法做成片剂,或采用常规方法制备成粉剂。
本发明的营养健康食品多糖含量在7.5%以上。
本发明中采用多糖含量的测定方法:
(1)多糖对照品溶液的制备:取无水葡萄糖对照品适量,精密称定,加水制成每1mL含0.12mg的溶液,即得。
(2)标准曲线的制备:精密量取对照品溶液0.2、0.4、0.6、0.8、1.0、1.2mL,分别置10mL具塞试管中,各加水至2.0mL,迅速精确加入硫酸蔥酮溶液(精密称取蔥酮0.lg,加硫酸100mL使溶解,摇匀)6mL,立即摇匀,放置15分钟后,立即置冰浴中冷却15分钟,取出,以相应的试剂为空白,照紫外-可见分光光度法,在625nm波长处测定吸光度,以吸光度为纵坐标,浓度为横坐标,绘制标准曲线。
供试品溶液的制备取本品粉末约2g,精密称定,置圆底烧瓶中,加水60mL静置1小时,加热固流4小时,趁热滤过,用少量热水洗涤滤器和滤渣,将滤渣及滤纸置烧瓶中,加水60mL,加热回流3小时,趁热滤过,合并滤液,置水浴上蒸干。
残渣用水5mL溶解,边搅拌边缓慢滴加乙醇75mL,摇匀,在4℃放置12小时,离心,弃去上清液,沉淀物用热水溶解并转移至50mL量瓶中,放冷,加水至刻度,摇匀,取溶液适量,离心,精密量取上清液3mL置25mL量瓶中,加水至刻度,摇匀,即得。
(3)测定法:精密量取供试品溶液2mL,置10mL具塞试管中,照标准曲线制备项下的方法,自“迅速精密加入硫酸蔥酮溶液6mL”起,同法操作,测定吸光度,从标准曲线上读出供试品溶液中无水葡萄糖的含量,计算,即得。
本发明中所采用的灵芝菌丝粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽均为为原国家卫生部批准的新资源食品。本发明中原料均可从市场上购买得到,无需特别制备。
本发明中的灵芝菌丝体,它具有抗血小板聚集及抗血栓、对抗急性心肌缺血、保肝、保护放化疗损伤、抗炎、抗氧化、延缓衰老和免疫调节等功效。
本发明中活性地龙蛋白含有胶原酶、纤溶酶和蚓激酶等多种成分,其分子量在1000~10000道尔顿,属于短链小分子物质。它具有如下几个特性:
1、溶解新鲜及陈旧性血栓。活性地龙蛋白中富含的纤溶酶、纤溶酶原激活物和胶原酶,不仅能溶解新鲜血栓,还能溶解陈旧性血栓,对心脑血管病的预防,中风后遗症的康复起到有效的作用。
2、改善全身微循环:活性地龙蛋白能溶解微血管内的微栓,让硬化的微血管恢复弹性,从而解除微血管的堵塞、扭曲变形情况,改善微循环。
3、软化血管,稳定斑块:活性地龙蛋白所含的纤维蛋白溶解酶和其它活性物质,能溶解粥样硬化管壁上纤维蛋白网状物,促进血管内皮细胞DNA的合成,使损伤的血管壁得以修复,恢复血管弹性,在一定程度上改变和阻止动脉硬化的病程。
4、建立侧枝循环,改善心脑供血供氧:活性地龙蛋白是地龙中的再生物质,能激活血管内皮细胞的分化特性,促进微血管再生,为病灶区的心脑组织开辟新的血液通路,建立侧枝循环。
5、双向调节血压:通过恢复血管弹性、溶解血栓、改善微循环,即可降低血流外周阻力,从而具有双向的稳定血压的作用。
6、降低血粘:活性地龙蛋白可减少血红细胞与白细胞的粘附,从而降低血液粘稠度。
本发明中大豆肽粉又称大豆多肽,它是由大豆蛋白经水解所得到的由3~6个氨基酸组成的低分子多肽,其分子量在1000道尔顿以下。大豆多肽的蛋白质含量为85%左右,其氨基酸组成几乎完全与大豆蛋白质一样,必需氨基酸的平衡良好,含量也丰富,具有传统多肽的优点。它比蛋白质更易被人体吸收,具有抗血栓、抑制血小板聚集、促进肠内双歧杆菌和乳酸菌的增殖、清除体内自由基,延缓衰老、促进矿物质及微量元素的吸收、抗疲劳和调节免疫等作用。
本发明中海洋鱼低聚肽是以海产鳕鱼皮为原料,经酶水解、精虑、浓缩、喷雾干燥而成。蛋白质含量稳定在90%以上,含有19种氨基酸,无腥味,保留了原鳕鱼皮中的所有营养成。海洋鱼低聚肽粉很容易被人体吸收,因其分子量仅为1000道尔顿以下的小分子海洋鱼低聚肽,吸收度极高,水溶性极强,迅速渗透到真皮,完全吸收。海洋鱼低聚肽的作用:1.能够有效解决皮肤及肌肉水分减少问题,适时补充胶原肽,能使皮肤保持年轻。2.使钙质与骨细胞紧密结合,不会流失或退化。3.能使眼角膜保持湿润透明,增加眼睛透明度。4.促使肌肉细胞紧密连结,使其具有弹性及光泽。5.调节内分泌、保护及强化内脏功能。6.结合免疫球蛋白,增加免疫力。
大豆磷脂是一种混合磷脂,它是由磷脂酰胆碱(卵磷脂,简称PC,高等级为PPC)、磷脂酰乙醇胺(脑磷脂,简称PE)、磷脂酰肌醇(肌醇磷脂,简称PI)、磷脂酰丝胺酸(丝胺酸磷脂,简称PS)等成分组成,其中最典型的是前三种。卵磷脂具有预防脂肪肝,降低血清胆固醇含量,防止肝硬化;调节糖尿病患者血糖浓度;增进血液循环,改善血清脂质,清除过氧化物,使血液中胆固醇及中性脂肪含量降低;减缓记忆力衰退的进程,预防或推迟老年痴呆等作用。
螺旋藻,它具有提高免疫力、调节机体多种生理功能、促进新陈代谢、抗衰老、抗凝血、抗疲劳等作用。
异麦芽酮糖醇适合糖尿病病人食用,不会引起血糖和胰岛素上升。
硬脂酸镁主要是做为赋形剂。
本发明的营养健康食品符合国家食品的相关要求。
本发明的优点:
1、本发明的含灵芝菌丝体营养健康食品具有抗凝抗栓、降低血脂,平衡血压,预防心脑血管疾病,保肝、保护放化疗损伤、抗炎、抗氧化、延缓衰老和免疫调节等功效;同时融入了活性地龙蛋白,大豆磷脂,使得本发明食品的抗凝抗栓,调节血脂,降低血液粘度,加快血流速度,改善血液循环,提高单位时间内细胞供氧能力,对防治心脑血管疾病的作用得到了增强,形成增效作用。本发明中的大豆肽粉和海洋鱼低聚肽又相互促进,相互融合,增强提高人体免疫力,起到抗衰老的作用,可消除皮肤皱纹和斑点、美容养颜。
2、本发明的食品适用人群范围广,中风、高血脂、糖尿病等特殊人群均适合食用。大豆磷脂,可以提供卵磷脂,起到平衡胰岛素分泌的作用。
3、本发明的食品有益于人体吸收,加入营养丰富的大豆肽粉和海洋鱼低聚肽,其均含有18种氨基酸,对胃肠功能低下,吸收功能欠缺或稍差的人群来说,本发明的食品更有利于人体吸收。
4、本发明采用合理、科学的配比来生产含灵芝菌丝体营养健康食品,使得原料成分之间的功效在进入人体之后能够起到相互促进作用,增强食品的保健功效,使得其降低血脂,预防脂肪肝,延缓老年痴呆等作用更为明显。
5、本发明所采用的原料均是国家卫生部批准的既是食品又是药品的物品或新资源食品,营养价值丰富,属于纯天然食品;经过采用合理配比制备成的灵芝菌丝体营养健康食品品,既保留了原料的营养价值,同时起到了防病治病的功效,食用有益于人体健康,同时丰富了国内外灵芝菌丝体食品品种。
6、本发明中提高灵芝菌丝粉和活性地龙蛋白的用量,增强食品的抗氧化、延缓衰老,调节血脂,降低血液粘度,平衡血压,预防心脑血管疾病等方面的功效,在多肽的运送作用下易于被人体吸收。
具体实施例
下面结合具体实例来对本发明做进一步的说明,但本发明的保护范围并不局限实施例表示的范围。
实施例1
配方:灵芝菌丝体粉50kg、活性地龙蛋白40kg、大豆肽粉10kg、海洋鱼低聚肽10kg、螺旋藻10kg、大豆磷脂5kg、异麦芽酮糖醇5kg、硬脂酸镁1kg。
制备方法:将上述灵芝菌丝体粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽、螺旋藻、大豆磷脂、异麦芽酮糖醇和硬脂酸镁充分粉碎混合,搅拌均匀,其中灵芝菌丝体粉、活性地龙蛋白要过100目筛;经消毒后,按常规方法制成片剂,每片0.5g。
制备得到的含灵芝菌丝体的营养健康食品,其多糖含量为7.5%以上。
实施例2
配方:灵芝菌丝体粉65kg、活性地龙蛋白55kg、大豆肽粉25kg、海洋鱼低聚肽15kg、螺旋藻15kg、大豆磷脂10kg、异麦芽酮糖醇10kg、硬脂酸镁3kg。
制备方法:将上述灵芝菌丝体粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽、螺旋藻、大豆磷脂、异麦芽酮糖醇和硬脂酸镁充分粉碎混合,搅拌均匀,其中灵芝菌丝体粉、活性地龙蛋白要过100目筛;经消毒后,按常规方法制成片剂,每片0.7g。
制备得到的含灵芝菌丝体的营养健康食品,其多糖含量为9.7%以上。
实施例3
配方:灵芝菌丝体粉60kg、活性地龙蛋白50kg、大豆肽粉10kg、海洋鱼低聚肽8kg、螺旋藻15kg、大豆磷脂6kg、异麦芽酮糖醇8kg、硬脂酸镁1kg。
制备方法:将上述灵芝菌丝体粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽、螺旋藻、大豆磷脂、异麦芽酮糖醇和硬脂酸镁充分粉碎混合,搅拌均匀,其中灵芝菌丝体粉、活性地龙蛋白要过100目筛;经消毒后,按常规方法制成胶囊,每粒0.3g。
制备得到的含灵芝菌丝体的营养健康食品,其多糖含量为9.0%以上。
实施例4
配方:灵芝菌丝体粉55kg、活性地龙蛋48kg、大豆肽粉15kg、海洋鱼低聚肽5kg、螺旋藻15kg、大豆磷脂8kg、异麦芽酮糖醇6kg、硬脂酸镁2kg。
制备方法:将上述灵芝菌丝体粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽、螺旋藻、大豆磷脂、异麦芽酮糖醇和硬脂酸镁充分粉碎混合,搅拌均匀,其中灵芝菌丝体粉、活性地龙蛋白要过100目筛;经消毒后,按常规方法制成胶囊,每粒0.25g。
制备得到的含灵芝菌丝体的营养健康食品,其多糖含量为8.2%以上。
实施例5
配方:灵芝菌丝体粉58kg、活性地龙蛋白45kg、大豆肽粉18kg、海洋鱼低聚肽10kg、、螺旋藻10kg、大豆磷脂10kg、异麦芽酮糖醇9kg、硬脂酸镁3kg。
制备方法:将上述灵芝菌丝体粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽、螺旋藻、大豆磷脂、异麦芽酮糖醇和硬脂酸镁充分粉碎混合,搅拌均匀,其中灵芝菌丝体粉、活性地龙蛋白要过80目筛;经消毒后,按常规方法制成袋装粉剂,每袋5g。
制备得到的含灵芝菌丝体的营养健康食品,其多糖含量为8.7%以上。
实施例6
配方:灵芝菌丝体粉55kg,活性地龙蛋白45kg,大豆肽粉10kg,海洋鱼低聚肽10kg,螺旋藻10kg,大豆磷脂10kg,异麦芽酮糖醇5,硬脂酸镁1kg。
制备方法:将上述灵芝菌丝体粉、活性地龙蛋白、大豆肽粉、海洋鱼低聚肽、螺旋藻、大豆磷脂、异麦芽酮糖醇和硬脂酸镁充分粉碎混合,搅拌均匀,其中灵芝菌丝体粉、活性地龙蛋白要过100目筛;经消毒后,按常规方法制成袋装粉剂,每袋5g。
制备得到的含灵芝菌丝体的营养健康食品,其多糖含量为9.0%以上。
产品临床应用效果:
病倒1:李某,男,58岁,广西某企业员工,患有糖尿病,身体免疫力差,经常感冒发烧。2014年5月开始服用按照本发明实施例3制备而成的产品,每天一粒,连续3个月,期间并没有因为服用本发明产品而引起血糖升高。三个月后明显的免疫力增强,日常小病概率明显降低,体力逐渐好装。
病倒2:张某,男,68岁,广西陆川县某村村民,换有轻微的高血压、高血糖,此前需要服用降压药物。2015年8月开始服用按本发明实施例4制备而成的多肽食品,每天一粒,连续6个月。前三个月还需要每隔1-2天服用一次降压药,后三个月开始,每隔4-5天才服用一次降压药。张某持续服用本发明产品9个月后,血压、血糖日常处于正常状态,无需靠降压药来维持,同时身体的免疫力也明显增强。
病倒3:王某,女,75岁,广西南宁市单位退休职工。患有轻微的老年痴呆症,行为反应迟缓。2016年1月开始服用按本发明实施例2制备而成的多肽食品,每天一片,连续服用6个月。6个月后,王某的反应能力得到了提高,对于旁人的交流能较快作出反应,同时身体的免疫力也明显增强。
Claims (6)
1.一种含灵芝菌丝体的营养健康食品,其特征在于:它的原料及重量份数为:灵芝菌丝体粉50~65份,活性地龙蛋白40~65份,大豆肽粉10~25份,海洋鱼低聚肽10~15份,螺旋藻10~15份,大豆磷脂5~10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份。
2.根据权利要求1所述的含灵芝菌丝体的营养健康食品,其特征在于:它的原料及重量份数为:灵芝菌丝体粉55~60份,活性地龙蛋白45~50份,大豆肽粉10~15份,海洋鱼低聚肽5~10份,螺旋藻5~10份,大豆磷脂5~10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份。
3.根据权利要求1所述的含灵芝菌丝体的营养健康食品,其特征在于:它的原料及重量份数为:灵芝菌丝体粉55份,活性地龙蛋白45份,大豆肽粉10份,海洋鱼低聚肽10份,螺旋藻10份,大豆磷脂10份,异麦芽酮糖醇5~10份,硬脂酸镁1~3份。
4.根据权利要求1所述的含灵芝菌丝体的营养健康食品,其特征在于:所述多肽食品为片剂、胶囊剂或粉剂。
5.根据权利要求1所述的含灵芝菌丝体的营养健康食品,其特征在于:所述营养健康食品的多糖含量在7.5%以上。
6.根据权利要求1所述的含灵芝菌丝体的营养健康食品,其特征在于:所述灵芝菌丝粉和活性地龙蛋白过60~150目筛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710345834.XA CN107149140A (zh) | 2017-05-17 | 2017-05-17 | 一种含灵芝菌丝体的营养健康食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710345834.XA CN107149140A (zh) | 2017-05-17 | 2017-05-17 | 一种含灵芝菌丝体的营养健康食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107149140A true CN107149140A (zh) | 2017-09-12 |
Family
ID=59794161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710345834.XA Pending CN107149140A (zh) | 2017-05-17 | 2017-05-17 | 一种含灵芝菌丝体的营养健康食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107149140A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108142929A (zh) * | 2017-12-26 | 2018-06-12 | 周其燕 | 一种含蚕蛹健康营养食品 |
CN109007844A (zh) * | 2018-07-05 | 2018-12-18 | 王栋 | 一种功能性食品 |
CN110477396A (zh) * | 2019-09-11 | 2019-11-22 | 广西优未康生物科技有限公司 | 一种含竹叶黄酮的多肽食品 |
CN110870520A (zh) * | 2018-09-04 | 2020-03-10 | 天津星宇航天生物科技有限公司 | 一种适合航天员微循环改善的营养制品 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475146A (zh) * | 2003-06-01 | 2004-02-18 | 吴限同 | 系列保健食品 |
CN102823800A (zh) * | 2012-09-28 | 2012-12-19 | 邹军 | 一种含海洋鱼低聚肽的多肽营养健康食品 |
CN102993267A (zh) * | 2012-12-20 | 2013-03-27 | 西藏金稞集团有限责任公司 | 一种灵芝活性肽的制取方法 |
CN103211150A (zh) * | 2013-05-17 | 2013-07-24 | 胡凯 | 一种含活性地龙蛋白的多肽食品 |
CN104996989A (zh) * | 2015-04-08 | 2015-10-28 | 劲膳美生物科技股份有限公司 | 血瘀体质医学配方食品 |
CN105124600A (zh) * | 2015-08-24 | 2015-12-09 | 杭州娃哈哈科技有限公司 | 一种具有改善睡眠功能的组合物及其应用 |
-
2017
- 2017-05-17 CN CN201710345834.XA patent/CN107149140A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475146A (zh) * | 2003-06-01 | 2004-02-18 | 吴限同 | 系列保健食品 |
CN102823800A (zh) * | 2012-09-28 | 2012-12-19 | 邹军 | 一种含海洋鱼低聚肽的多肽营养健康食品 |
CN102993267A (zh) * | 2012-12-20 | 2013-03-27 | 西藏金稞集团有限责任公司 | 一种灵芝活性肽的制取方法 |
CN103211150A (zh) * | 2013-05-17 | 2013-07-24 | 胡凯 | 一种含活性地龙蛋白的多肽食品 |
CN104996989A (zh) * | 2015-04-08 | 2015-10-28 | 劲膳美生物科技股份有限公司 | 血瘀体质医学配方食品 |
CN105124600A (zh) * | 2015-08-24 | 2015-12-09 | 杭州娃哈哈科技有限公司 | 一种具有改善睡眠功能的组合物及其应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108142929A (zh) * | 2017-12-26 | 2018-06-12 | 周其燕 | 一种含蚕蛹健康营养食品 |
CN109007844A (zh) * | 2018-07-05 | 2018-12-18 | 王栋 | 一种功能性食品 |
CN110870520A (zh) * | 2018-09-04 | 2020-03-10 | 天津星宇航天生物科技有限公司 | 一种适合航天员微循环改善的营养制品 |
CN110477396A (zh) * | 2019-09-11 | 2019-11-22 | 广西优未康生物科技有限公司 | 一种含竹叶黄酮的多肽食品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8927523B2 (en) | Compound sea cucumber preparation and manufacturing method thereof | |
CN103211150B (zh) | 一种含活性地龙蛋白的多肽食品 | |
CN107149140A (zh) | 一种含灵芝菌丝体的营养健康食品 | |
CN101696444B (zh) | 多肽提取物及其制备方法和应用 | |
CN104068302A (zh) | 一种浒苔多糖口服液及其制备方法 | |
CN103919920A (zh) | 一种保持枸杞子原生态的口含片及其制备工艺 | |
CN109331038A (zh) | 一种鹿血晶的生产工艺及其保健品的制备方法 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN106942578A (zh) | 一种控制嘌呤摄入及促进尿酸排泄的天然膳食 | |
CN101803661B (zh) | 木耳茶 | |
CN102028230B (zh) | 一种保健品辅料及其应用 | |
CN105029449A (zh) | 一种保健食品 | |
CN106924549A (zh) | 一种具有补气养血功能的组合物及提取物的制备方法与应用 | |
CN101336705B (zh) | 保健食品及其制备方法 | |
JPH1075750A (ja) | にんにく系健康飲料 | |
CN105941768A (zh) | 一种含有灵芝菌丝的金花茶 | |
CN104189038B (zh) | 用于调理女性生理健康和免疫功能的中药制剂 | |
CN106173128A (zh) | 一种具有抗疲劳功效的巧克力及其制备方法 | |
CN111227229A (zh) | 一种植物源营养粉及其制备方法和食用方法 | |
CN103610123A (zh) | 一种海参和蛋白小球藻浆液制品及其制备方法 | |
CN110477396A (zh) | 一种含竹叶黄酮的多肽食品 | |
CN103989720A (zh) | 一种复合氨基酸生晒参胶囊制备方法 | |
CN103355664B (zh) | 一种含大鲵骨的胶囊及其制备方法 | |
TW201819623A (zh) | 用於降低膽紅素位準之組成物及方法 | |
CN107006653A (zh) | 一种西蓝花幼苗三泡台茶的生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170912 |